Condition: Ovarian Cancer · Oligometastatic Disease · Serous Ovarian Tumor · Sponsor: MedSIR
The ANALLISA study is a fast, proof-of-concept, phase II clinical trial which aims to assess the efficacy of niraparib rechallenge treatment after secondary cytoreductive surgery in ovarian cancer (OC) patients with oligometastatic progression (OMP) after first maintenance therapy with any PARP inhibitor. A total of 30 patients with OC and OMP will be enrolled and will receive treatment with niraparib 300 or 200 mg, according to body weight or platelet count. Patients will start treatment within 8 weeks after surgery and will receive it until progressive disease or treatment discontinuation. The main purpose of the study is to evaluate progression-free survival (PFS) of niraparib rechallenge in OC patients with OMP and no residual disease after secondary cytoreductive surgery.
This description comes directly from the study's public registry record.
MEDSIR · + 34 932 214 135 · contact.trials@medsir.org
Always discuss trial participation with your own doctor first.
| Complejo Hospitalario Universitario A Coruña (CHUAC) | A Coruña, Spain | Recruiting |
| Hospital de Cruces | Barakaldo, Spain | Recruiting |
| Hospital Universitari Vall D'Hebron | Barcelona, Spain | Recruiting |
| Institut Català d' Oncologia Girona (ICO) | Girona, Spain | Recruiting |
| Complejo Hospitalario de Jaén | Jaén, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
| Hospital Universitario La Paz | Madrid, Spain | Recruiting |
| Hospital Universitario Ramón y Cajal | Madrid, Spain | Recruiting |
| Hospital Universitario Virgen de la Victoria | Málaga, Spain | Recruiting |
| Hospital Universitario Central de Asturias (HUCA) | Oviedo, Spain | Recruiting |
| Hospital Universitario Virgen Macarena | Seville, Spain | Recruiting |
| Hospital Universitari Sant Joan de Reus | Tarragona, Spain | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06180356